Publications

2024

• INHBA is enriched in HPV-negative oropharyngeal squamous cell carcinoma and promotes cancer progression.
  Abou Kors T, Hofmann L, Betzler A, Payer K, Bens M, Truong J, von Witzleben A, Thomas J, Kraus JM, Kalaajieh R, Huber D, Ezić J, Benckendorff J, Greve J, Schuler PJ, Ottensmeier CH, Kestler HA, Hoffmann TK, Theodoraki MN, Brunner C, Laban S
  Cancer Res Commun 2024, 4(2), 571-87
  
• Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens.
  Abou Kors T, Meier M, Mühlenbruch L, Betzler AC, Oliveri F, Bens M, Thomas J, Kraus JM, Doescher J, von Witzleben A, Hofmann L, Ezic J, Huber D, Benckendorff J, Barth TFE, Greve J, Schuler PJ, Brunner C, Blackburn JM, Hoffmann TK, Ottensmeier C, Kestler HA, Rammensee HG, Walz JS, Laban S
  Front Immunol 2024, 15, 1408173
  
• Hydra has mammal-like mutation rates facilitating fast adaptation despite its nonaging phenotype.
  Sahm A, Riege K, Groth M, Bens M, Kraus J, Fischer M, Kestler H, Englert C, Schaible R, Platzer M, Hoffmann S
  Genome Res 2024, 34(12), 2217-28
  

2023

• Liquid biopsy: an examination of platelet RNA obtained from head and neck squamous cell carcinoma patients for predictive molecular tumor markers.
  Huber* LT, Kraus* JM, Ezić* J, Wanli A, Groth M, Laban S, Hoffmann TK, Wollenberg B, Kestler** HA, Brunner** C
  Explor Target Antitumor Ther 2023, 4(3), 422–446 * equal contribution, ** co-corresponding authors
  
• The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
  Mühlenbruch L, Abou-Kors T, Dubbelaar ML, Bichmann L, Kohlbacher O, Bens M, Thomas J, Ezić J, Kraus JM, Kestler HA, von Witzleben A, Mytilineos J, Fürst D, Engelhardt D, Doescher J, Greve J, Schuler PJ, Theodoraki MN, Brunner C, Hoffmann TK, Rammensee HG, Walz JS, Laban S
  Br J Cancer 2023, 128(9), 1777-87